WP
FHTX icon

Woodline Partners’s Foghorn Therapeutics FHTX Stock Holding History

Woodline Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$862K Buy
180,333
+158,810
+738% +$872K ﹤0.01% 903
2025
Q4 		$116K Sell
21,523
-87,073
-80% -$395K ﹤0.01% 1008
2025
Q3 		$531K Buy
+108,596
New +$576K ﹤0.01% 833
2021
Q1 		– Sell
-103,040
Closed -$2.09M – 444
2020
Q4 		$2.09M Buy
+103,040
New +$1.97M 0.06% 194

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Woodline Partners's FHTX Position: Q1 2026 in Review

Woodline Partners increased its Foghorn Therapeutics (FHTX) stake by 738% in Q1 2026, buying an estimated $872K and bringing the position to 180,333 shares worth $862K. The position accounts for ﹤0.01% of the portfolio, ranked #903.

Woodline Partners first reported a position in FHTX in Q4 2020 and has held it in 4 quarters since. The position peaked at $2.09M in Q4 2020. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Woodline Partners held 180,333 shares of Foghorn Therapeutics worth $862K as of Q1 2026.
  • Woodline Partners bought 158,810 Foghorn Therapeutics shares in Q1 2026, an estimated $872K.
  • Foghorn Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #903 holding.
  • Woodline Partners first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • Woodline Partners's Foghorn Therapeutics position peaked at $2.09M in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.